Osimertinib (AZD-9291) CAS 1421373-65-0 | Chemical Supplier

AZD-9291 (Osimertinib), marketed as Tagrisso, is a third-generation, oral, irreversible skin development aspect receptor (EGFR) tyrosine kinase prevention (TKI) established by AstraZeneca. Its key worth hinges on getting over resistance obstacles in targeted lung cancer cells therapy. The CAS number for this compound is 1421373-65-0.

In regards to device, AZD-9291’s high selectivity is its most remarkable attribute. It not just potently inhibits EGFR sensitizing anomalies (such as L858R and exon 19 deletion), however more notably, it targets the T790M anomaly– in charge of resistance– with remarkably high task (IC50 as low as 1 nM). At the same time, its restraint of wild-type EGFR (IC50 of 480 nM) is dramatically weaker than that against mutant kinds. This distinction allows it to precisely target cancer cells while substantially minimizing adverse effects such as rash and looseness of the bowels.

In professional applications, AZD-9291 is an essential medication for treating EGFR-mutated non-small cell lung cancer cells. The FDA has provided it orphan drug classification and authorized multiple indicators, including second-line therapy for individuals with T790M resistance mutations, first-line therapy for clients with EGFR-sensitive anomalies, adjuvant treatment for post-surgical people, and combination with chemotherapy for first-line therapy. As a result of its high expense, countries such as Bangladesh offer lawfully produced generics (e.g., Alvonib), giving more alternatives in the market.